Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 96

Similar articles for PubMed (Select 23069874)

1.

Randomised multicentre trial on safety and efficacy of rivastigmine in cognitively impaired multiple sclerosis patients.

Mäurer M, Ortler S, Baier M, Meergans M, Scherer P, Hofmann W, Tracik F.

Mult Scler. 2013 Apr;19(5):631-8. doi: 10.1177/1352458512463481. Epub 2012 Oct 15.

PMID:
23069874
2.

Effects of rivastigmine on memory and cognition in multiple sclerosis.

Shaygannejad V, Janghorbani M, Ashtari F, Zanjani HA, Zakizade N.

Can J Neurol Sci. 2008 Sep;35(4):476-81.

PMID:
18973065
3.

Cholinesterase inhibitors for Alzheimer's disease.

Birks J.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005593. Review.

PMID:
16437532
4.

The effects of rivastigmine on processing speed and brain activation in patients with multiple sclerosis and subjective cognitive fatigue.

Huolman S, Hämäläinen P, Vorobyev V, Ruutiainen J, Parkkola R, Laine T, Hämäläinen H.

Mult Scler. 2011 Nov;17(11):1351-61. doi: 10.1177/1352458511412061. Epub 2011 Aug 16.

PMID:
21846692
5.

Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study.

Feldman HH, Ferris S, Winblad B, Sfikas N, Mancione L, He Y, Tekin S, Burns A, Cummings J, del Ser T, Inzitari D, Orgogozo JM, Sauer H, Scheltens P, Scarpini E, Herrmann N, Farlow M, Potkin S, Charles HC, Fox NC, Lane R.

Lancet Neurol. 2007 Jun;6(6):501-12. Erratum in: Lancet Neurol. 2007 Oct;6(10):849.

PMID:
17509485
6.

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial.

Rösler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stähelin HB, Hartman R, Gharabawi M.

BMJ. 1999 Mar 6;318(7184):633-8. Erratum in: BMJ 2001 Jun 16;322(7300):1456.

7.

Rivastigmine for Alzheimer's disease.

Birks J, Grimley Evans J, Iakovidou V, Tsolaki M, Holt FE.

Cochrane Database Syst Rev. 2009 Apr 15;(2):CD001191. doi: 10.1002/14651858.CD001191.pub2. Review.

PMID:
19370562
8.
9.

Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period.

Bullock R, Touchon J, Bergman H, Gambina G, He Y, Rapatz G, Nagel J, Lane R.

Curr Med Res Opin. 2005 Aug;21(8):1317-27.

PMID:
16083542
10.

Rivastigmine for Alzheimer's disease.

Birks J, Iakovidou V, Tsolaki M.

Cochrane Database Syst Rev. 2000;(2):CD001191. Review. Update in: Cochrane Database Syst Rev. 2000;(4):CD001191.

PMID:
10796621
11.

Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial.

Ballard C, Margallo-Lana M, Juszczak E, Douglas S, Swann A, Thomas A, O'Brien J, Everratt A, Sadler S, Maddison C, Lee L, Bannister C, Elvish R, Jacoby R.

BMJ. 2005 Apr 16;330(7496):874. Epub 2005 Feb 18.

12.

Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.

Rolinski M, Fox C, Maidment I, McShane R.

Cochrane Database Syst Rev. 2012 Mar 14;3:CD006504. doi: 10.1002/14651858.CD006504.pub2. Review.

PMID:
22419314
14.

Rivastigmine for cognitive impairment after spontaneous subarachnoid haemorrhage: a pilot study.

Wong GK, Wong R, Mok V, Wong A, Fan D, Leung G, Chan A, Poon WS.

J Clin Pharm Ther. 2009 Dec;34(6):657-63. doi: 10.1111/j.1365-2710.2009.01056.x.

PMID:
20175798
15.

Rivastigmine for Alzheimer's disease.

Birks J, Grimley Evans J, Iakovidou V, Tsolaki M.

Cochrane Database Syst Rev. 2000;(4):CD001191. Review. Update in: Cochrane Database Syst Rev. 2009;(2):CD001191.

PMID:
11034705
16.

Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years.

Small GW, Kaufer D, Mendiondo MS, Quarg P, Spiegel R.

Int J Clin Pract. 2005 Apr;59(4):473-7. Review.

PMID:
15853867
17.

Rivastigmine for dementia associated with Parkinson's disease.

Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, Durif F, Kulisevsky J, van Laar T, Lees A, Poewe W, Robillard A, Rosa MM, Wolters E, Quarg P, Tekin S, Lane R.

N Engl J Med. 2004 Dec 9;351(24):2509-18.

18.

Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression.

Farlow MR, Hake A, Messina J, Hartman R, Veach J, Anand R.

Arch Neurol. 2001 Mar;58(3):417-22.

PMID:
11255445
19.
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk